Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Eiger Biopharma (EIGR)

Eiger Biopharma (EIGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 243,089
  • Shares Outstanding, K 33,951
  • Annual Sales, $ 0 K
  • Annual Income, $ -65,050 K
  • 60-Month Beta 1.34
  • Price/Sales 40.79
  • Price/Cash Flow N/A
  • Price/Book 2.50
Trade EIGR with:

Options Overview Details

View History
  • Implied Volatility 66.73%
  • Historical Volatility 28.70%
  • IV Percentile 4%
  • IV Rank 7.80%
  • IV High 156.19% on 10/14/20
  • IV Low 59.16% on 08/11/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 15
  • Volume Avg (30-Day) 178
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 603

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.54
  • Number of Estimates 2
  • High Estimate -0.50
  • Low Estimate -0.58
  • Prior Year -0.52
  • Growth Rate Est. (year over year) -3.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.80 +5.29%
on 09/20/21
8.40 -14.76%
on 09/02/21
-0.87 (-10.83%)
since 08/27/21
3-Month
6.80 +5.29%
on 09/20/21
9.57 -25.18%
on 06/28/21
-1.51 (-17.42%)
since 06/25/21
52-Week
6.80 +5.29%
on 09/20/21
13.49 -46.92%
on 02/10/21
-2.73 (-27.60%)
since 09/25/20

Most Recent Stories

More News
Eiger BioPharmaceuticals Appoints Erik Atkisson as General Counsel and Chief Compliance Officer

Sept. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious...

EIGR : 7.16 (+2.29%)
Eiger BioPharmaceuticals Announces Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients

PALO ALTO, Calif., Sept. 20, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted...

EIGR : 7.16 (+2.29%)
Eiger BioPharmaceuticals to Participate in Upcoming September 2021 Investor Conferences

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare...

EIGR : 7.16 (+2.29%)
Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -5.56% and 29.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

EIGR : 7.16 (+2.29%)
Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and...

EIGR : 7.16 (+2.29%)
Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare...

EIGR : 7.16 (+2.29%)
Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare...

EIGR : 7.16 (+2.29%)
Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and...

EIGR : 7.16 (+2.29%)
Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and...

EIGR : 7.16 (+2.29%)
Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare...

EIGR : 7.16 (+2.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California.

See More

Key Turning Points

3rd Resistance Point 7.66
2nd Resistance Point 7.48
1st Resistance Point 7.32
Last Price 7.16
1st Support Level 6.98
2nd Support Level 6.80
3rd Support Level 6.64

See More

52-Week High 13.49
Fibonacci 61.8% 10.93
Fibonacci 50% 10.15
Fibonacci 38.2% 9.36
Last Price 7.16
52-Week Low 6.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar